Short- and long-term outcomes in patients operated with total minimally invasive esophagectomy for esophageal cancer.

Autor: Hauge T; Department of Pediatric and Gastrointestinal Surgery, Oslo University Hospital, Oslo, Norway.; Institute of Clinical medicine, Department of Gastrointestinal and Children Surgery, University of Oslo, Oslo, Norway., Førland DT; Department of Pediatric and Gastrointestinal Surgery, Oslo University Hospital, Oslo, Norway., Johannessen HO; Department of Pediatric and Gastrointestinal Surgery, Oslo University Hospital, Oslo, Norway., Johnson E; Department of Pediatric and Gastrointestinal Surgery, Oslo University Hospital, Oslo, Norway.; Institute of Clinical medicine, Department of Gastrointestinal and Children Surgery, University of Oslo, Oslo, Norway.
Jazyk: angličtina
Zdroj: Diseases of the esophagus : official journal of the International Society for Diseases of the Esophagus [Dis Esophagus] 2022 May 10; Vol. 35 (5).
DOI: 10.1093/dote/doab061
Abstrakt: At our hospital, the main treatment for resectable esophageal cancer (EC) has since 2013 been total minimally invasive esophagectomy (TMIE). The aim of this study was to present the short- and long-term results in patients operated with TMIE. This cross-sectional study includes all patients scheduled for TMIE from June 2013 to January 2016 at Oslo University Hospital. Data on morbidity, mortality, and survival were retrospectively collected from the patient administration system and the Norwegian Cause of Death Registry. Long-term postoperative health-related quality of life (HRQL) and level of dysphagia were assessed by patients completing the following questionaries: EORTC QLQ-OG25, QLQ-C30, and the Ogilvie grading scale. A total of 123 patients were included in this study with a median follow-up time of 58 months (1-88 months). 85% had adenocarcinoma, 15% squamous cell carcinoma. Seventeen patients (14%) had T1N0M0, 68 (55%) T2-T3N0M0, or T1-T2N1M0 and 38 (31%) had either T3N1M0 or T4anyNM0. Ninety-eight patients (80%) received neoadjuvant (radio)chemotherapy and 104 (85%) had R0 resection. Anastomotic leak rate and 90-days mortality were 14% and 2%, respectively. The 5-year overall survival was 53%. Patients with tumor free resection margins of >1 mm (R0) had a 5-year survival of 57%. Median 60 months (range 49-80) postoperatively the main symptoms reducing HRQL were anxiety, chough, insomnia, and reflux. Median Ogilvie score was 0 (0-1). In this study, we report relatively low mortality and good overall survival after TMIE for EC. Moreover, key symptoms reducing long-term HRQL were identified.
(© The Author(s) 2021. Published by Oxford University Press on behalf of International Society for Diseases of the Esophagus. All rights reserved. For permissions, please e-mail: journals.permissions@oup.com.)
Databáze: MEDLINE
Externí odkaz:
Nepřihlášeným uživatelům se plný text nezobrazuje